title: A case report of adenocarcinoma of the lung in which a partial response was achieved by carboplatin.
abstract: A 56-year-old housewife was incidentally discovered to have an abnormal shadow in the right B6 area upon a chest X-ray film being taken. A transcutaneous lung biopsy of the mass revealed adenocarcinoma of the lung (WHO classification). A brain computed tomography (CT) scan demonstrated multiple brain metastasis. Following whole brain irradiation, carboplatin (CBDCA) (450 mg/m2) was administered by intravenous drip infusion on March 7, 1986. After three weeks of initial treatment with CBDCA, the size of the tumor in the primary site was found to have decreased on the chest X-ray film by more than 50%, following which, similar doses of CBDCA were administered twice, and reduced (330 mg/m2) doses three times every three to four weeks. She showed a partial response and, for seven months after the beginning of the CBDCA treatment, no progression was seen on the chest X-ray film. It is suggested that there is a need for further phase II studies of CBDCA against non-small cell lung cancer.
authors.forename: T
authors.initials: T
authors.lastname: Akiba
authors.forename: N
authors.initials: N
authors.lastname: Saijo
authors.forename: K
authors.initials: K
authors.lastname: Miyamoto
authors.forename: J
authors.initials: J
authors.lastname: Taguchi
authors.forename: H
authors.initials: H
authors.lastname: Taito
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
authors.forename: T
authors.initials: T
authors.lastname: Tamura
authors.forename: Y
authors.initials: Y
authors.lastname: Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Eguchi
authors.forename: T
authors.initials: T
authors.lastname: Shinkai
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary; D016190:Carboplatin; D003131:Combined Modality Therapy; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008175:Lung Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin